EFFECT OF ARGININE VASOPRESSIN AND PARATHYROID HORMONE‐RELATED PROTEIN ON RENAL FUNCTION IN THE OVINE FOETUS

Rosemary S.C. Horne, Richard J. MacIsaac, Karen M. Moritz, Kathy Tangalakis, E. Marelyn Wintour

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)

Abstract

1. The effects of intravenous infusions of arginine vasopressin (AVP), parathyroid hormone‐related protein (PTHrP) and AVP + PTHrP on renal function in intact ovine foetuses at 100–125 days of gestation were examined. 2. A low dose of AVP (5.5 ± 0.9 pmol/h) increased plasma AVP concentrations from 0.6 pmol/L to 2.1 ± 0.4 pmol/L (mean ± s.e.m; n= 8). This dose caused a significant reduction in free water clearance (CH2O; P<0.001), without any significant change in fetal arterial blood pressure, glomerular filtration rate (GFR), or the urinary excretion rates of sodium, calcium or 3', 5'‐cyclic adenosine monophosphate (CAMP). 3. Infusions of PTHrP (1 nmol/h), with or without 1 nmol bolus dose, significantly increased (P<0.05) urine osmolality (Uosm), but did not synergize with AVP in reducing CH2O. 4. It is concluded that AVP and PTHrP do not act synergistically on the kidney of the intact ovine foetus.

Original languageEnglish
Pages (from-to)569-577
Number of pages9
JournalClinical and Experimental Pharmacology and Physiology
Volume20
Issue number9
DOIs
Publication statusPublished - 1 Jan 1993

Keywords

  • arginine vasopressin
  • foetus
  • free water clearance
  • parathyroid hormone‐related protein.

Cite this

Horne, Rosemary S.C. ; MacIsaac, Richard J. ; Moritz, Karen M. ; Tangalakis, Kathy ; Wintour, E. Marelyn. / EFFECT OF ARGININE VASOPRESSIN AND PARATHYROID HORMONE‐RELATED PROTEIN ON RENAL FUNCTION IN THE OVINE FOETUS. In: Clinical and Experimental Pharmacology and Physiology. 1993 ; Vol. 20, No. 9. pp. 569-577.
@article{526605759fc4420f9705c5f44a2d5d84,
title = "EFFECT OF ARGININE VASOPRESSIN AND PARATHYROID HORMONE‐RELATED PROTEIN ON RENAL FUNCTION IN THE OVINE FOETUS",
abstract = "1. The effects of intravenous infusions of arginine vasopressin (AVP), parathyroid hormone‐related protein (PTHrP) and AVP + PTHrP on renal function in intact ovine foetuses at 100–125 days of gestation were examined. 2. A low dose of AVP (5.5 ± 0.9 pmol/h) increased plasma AVP concentrations from 0.6 pmol/L to 2.1 ± 0.4 pmol/L (mean ± s.e.m; n= 8). This dose caused a significant reduction in free water clearance (CH2O; P<0.001), without any significant change in fetal arterial blood pressure, glomerular filtration rate (GFR), or the urinary excretion rates of sodium, calcium or 3', 5'‐cyclic adenosine monophosphate (CAMP). 3. Infusions of PTHrP (1 nmol/h), with or without 1 nmol bolus dose, significantly increased (P<0.05) urine osmolality (Uosm), but did not synergize with AVP in reducing CH2O. 4. It is concluded that AVP and PTHrP do not act synergistically on the kidney of the intact ovine foetus.",
keywords = "arginine vasopressin, foetus, free water clearance, parathyroid hormone‐related protein.",
author = "Horne, {Rosemary S.C.} and MacIsaac, {Richard J.} and Moritz, {Karen M.} and Kathy Tangalakis and Wintour, {E. Marelyn}",
year = "1993",
month = "1",
day = "1",
doi = "10.1111/j.1440-1681.1993.tb01743.x",
language = "English",
volume = "20",
pages = "569--577",
journal = "Clinical and Experimental Pharmacology and Physiology",
issn = "0305-1870",
publisher = "Wiley-Blackwell",
number = "9",

}

EFFECT OF ARGININE VASOPRESSIN AND PARATHYROID HORMONE‐RELATED PROTEIN ON RENAL FUNCTION IN THE OVINE FOETUS. / Horne, Rosemary S.C.; MacIsaac, Richard J.; Moritz, Karen M.; Tangalakis, Kathy; Wintour, E. Marelyn.

In: Clinical and Experimental Pharmacology and Physiology, Vol. 20, No. 9, 01.01.1993, p. 569-577.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - EFFECT OF ARGININE VASOPRESSIN AND PARATHYROID HORMONE‐RELATED PROTEIN ON RENAL FUNCTION IN THE OVINE FOETUS

AU - Horne, Rosemary S.C.

AU - MacIsaac, Richard J.

AU - Moritz, Karen M.

AU - Tangalakis, Kathy

AU - Wintour, E. Marelyn

PY - 1993/1/1

Y1 - 1993/1/1

N2 - 1. The effects of intravenous infusions of arginine vasopressin (AVP), parathyroid hormone‐related protein (PTHrP) and AVP + PTHrP on renal function in intact ovine foetuses at 100–125 days of gestation were examined. 2. A low dose of AVP (5.5 ± 0.9 pmol/h) increased plasma AVP concentrations from 0.6 pmol/L to 2.1 ± 0.4 pmol/L (mean ± s.e.m; n= 8). This dose caused a significant reduction in free water clearance (CH2O; P<0.001), without any significant change in fetal arterial blood pressure, glomerular filtration rate (GFR), or the urinary excretion rates of sodium, calcium or 3', 5'‐cyclic adenosine monophosphate (CAMP). 3. Infusions of PTHrP (1 nmol/h), with or without 1 nmol bolus dose, significantly increased (P<0.05) urine osmolality (Uosm), but did not synergize with AVP in reducing CH2O. 4. It is concluded that AVP and PTHrP do not act synergistically on the kidney of the intact ovine foetus.

AB - 1. The effects of intravenous infusions of arginine vasopressin (AVP), parathyroid hormone‐related protein (PTHrP) and AVP + PTHrP on renal function in intact ovine foetuses at 100–125 days of gestation were examined. 2. A low dose of AVP (5.5 ± 0.9 pmol/h) increased plasma AVP concentrations from 0.6 pmol/L to 2.1 ± 0.4 pmol/L (mean ± s.e.m; n= 8). This dose caused a significant reduction in free water clearance (CH2O; P<0.001), without any significant change in fetal arterial blood pressure, glomerular filtration rate (GFR), or the urinary excretion rates of sodium, calcium or 3', 5'‐cyclic adenosine monophosphate (CAMP). 3. Infusions of PTHrP (1 nmol/h), with or without 1 nmol bolus dose, significantly increased (P<0.05) urine osmolality (Uosm), but did not synergize with AVP in reducing CH2O. 4. It is concluded that AVP and PTHrP do not act synergistically on the kidney of the intact ovine foetus.

KW - arginine vasopressin

KW - foetus

KW - free water clearance

KW - parathyroid hormone‐related protein.

UR - http://www.scopus.com/inward/record.url?scp=0027254862&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1681.1993.tb01743.x

DO - 10.1111/j.1440-1681.1993.tb01743.x

M3 - Article

VL - 20

SP - 569

EP - 577

JO - Clinical and Experimental Pharmacology and Physiology

JF - Clinical and Experimental Pharmacology and Physiology

SN - 0305-1870

IS - 9

ER -